

CITATION REPORT

List of articles citing

Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy

DOI: 10.1161/circulationaha.119.045093
Circulation, 2020, 141, 1214-1224.

Source: <https://exaly.com/paper-pdf/77228002/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
109	Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis. 2020 , 2, 414-424		13
108	Letter by Rozenbaum et al Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". <i>Circulation</i> , 2020 , 142, e210-e211	16.7	2
107	Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery. 2020 , 82, 7-15		15
106	Advances in the Diagnosis and Management of Transthyretin Amyloid Cardiomyopathy. 2020 , 22, 1		1
105	Editorial: F-Fluoride PET/MR in cardiac amyloid; simple addition versus synergy?. 2020 , 1		0
104	Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid. 2020 , 22, 106		1
103	Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence-Based Recommendations. 2020 , 9, e016614		3
102	Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines. 2020 , 16, 749-758		4
101	Full Issue PDF. 2020 , 2, I-LXXXIII		
100	Disease-Modifying Therapy for Transthyretin Amyloidosis: Where to Start? Where to Stop?. 2020 , 2, 2128-2130		1
99	Letter regarding the article Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. 2021 , 23, 681-682		0
98	Willingness to Pay for High-Cost Medications. <i>Circulation</i> , 2020 , 141, 1225-1226	16.7	1
97	Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2020 , 142, e7-e22	16.7	132
96	Orphan Drug Development in Cardiovascular Medicine. 2020 , 13, e006509		2
95	Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History. 2020 , 5, 1066-1067		9
94	V122I Transthyretin Cardiomyopathy: An Opportunity to Build Trust and Resolve Disparities. 2020 , 76, 93-95		1
93	Tafamidis not cost effective for transthyretin amyloid cardiomyopathy. 2020 , 848, 29-29		

92	Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). 2021 , 110, 479-506	17
91	Incidental detection of ATTR cardiac amyloidosis. 2021 , 1	0
90	Tafamidis: A Review in Transthyretin Amyloid Cardiomyopathy. 2021 , 21, 113-121	3
89	Amyloidosis. 2021 , 305-307	
88	Tafamidis for Cardiac Transthyretin Amyloidosis. 2021 , 3, 1	0
87	Transthyretin amyloid cardiomyopathy. 2021 , 156, 126-134	
86	Transthyretin amyloid cardiomyopathy. 2021 , 156, 126-134	6
85	Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy. 2021 , 9, 124-126	1
84	Updates in Cardiac Amyloidosis Diagnosis and Treatment. 2021 , 23, 47	5
83	Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis. 2021 , 28, 1835-1845	5
82	Health Impact of Tafamidis in Transthyretin Amyloid Cardiomyopathy patients: An Analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the Open-Label Long-term Extension Studies. 2021 ,	1
81	Cost-effectiveness and affordability of novel cardiovascular therapies: what physicians need to know. 2021 ,	3
80	Prediction Score-Guided Genetic Testing for Hypertrophic Cardiomyopathy. 2021 , 85, 675-676	
79	Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.. 2021 , 15, 1	2
78	Recent Advances and Current Dilemmas in the Diagnosis and Management of Transthyretin Cardiac Amyloidosis. 2021 , 10, e019840	4
77	A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy. 2021 , 12, 2725	16
76	Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. 2021 , 128, 1554-1575	11
75	Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy. 2021 , 8, 2856-2865	4

74	Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. 2021 , 23, 79		5
73	Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain. 2021 , 21, 1127-1133		
72	Prevalence and Prognostic Significance of Frailty Among Patients With Transthyretin Amyloidosis Cardiomyopathy. 2021 , 14, e008105		1
71	Effects of sporadic transthyretin amyloidosis frequently on the gallbladder and the correlation between amyloid deposition in the gallbladder and heart: A forensic autopsy-based histopathological evaluation. 2021 , 71, 530-537		1
70	Cost-Effectiveness of Hypertension Treatment by Pharmacists in Black Barbershops. <i>Circulation</i> , 2021 , 143, 2384-2394	16.7	9
69	The use of diflunisal for transthyretin cardiac amyloidosis: a review. 2021 , 1		8
68	Out-of-Pocket Annual Health Expenditures and Financial Toxicity From Healthcare Costs in Patients With Heart Failure in the United States. 2021 , 10, e022164		3
67	Is Rising Cardiovascular Spending a Good News or Bad News Story?. <i>Circulation</i> , 2021 , 144, 283-285	16.7	
66	Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. 2021 , 4, e2114501		9
65	Transthyretin amyloid fibrils alter primary fibroblast structure, function, and inflammatory gene expression. 2021 , 321, H149-H160		2
64	Spending on Cardiovascular Disease and Cardiovascular Risk Factors in the United States: 1996 to 2016. <i>Circulation</i> , 2021 , 144, 271-282	16.7	5
63	Yield of bone scintigraphy screening for transthyretin-related cardiac amyloidosis in different conditions: Methodological issues and clinical implications. 2021 , 51, e13665		0
62	Transthyretin Cardiac Amyloidosis and Novel Therapies to Treat This Not-so-rare Cause of Cardiomyopathy. 2021 , 29, 263-273		0
61	New Drugs for Heart Failure: What is the Evidence in Older Patients?. 2021 ,		1
60	Cardiac Amyloidosis Presenting with Pre-Excitation Syndrome, Heart Failure, and Severe Factor X Deficiency as Part of Systemic Amyloid Light-Chain (AL) Amyloidosis - A Fatal Combination. 2021 , 22, e933398		1
59	Financial burden, distress, and toxicity in cardiovascular disease. 2021 , 238, 75-84		4
58	The Price of Progress: Cost, Access, and Adoption of Novel Cardiovascular Drugs in Clinical Practice. 2021 , 23, 163		1
57	A potential pitfall in the use of Tc-PYP imaging for diagnosing cardiac ATTR amyloidosis. 2021 , 28, 2395-2398		1

56	Cardiovascular Diseases That Have Emerged From the Darkness. 2021 , 10, e021095	3
55	Wild type transthyretin amyloid cardiomyopathy. The Gordian-knot of novel therapeutic regimens.. 2021 , Publish Ahead of Print,	0
54	Advances in the treatment of transthyretin cardiac amyloidosis: Current and emerging therapies. 2021 , 41, 1081	0
53	Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy. 2020 , 2, 420-424	1
52	ATTR Amyloidosis: Current and Emerging Management Strategies: State-of-the-Art Review. 2021 , 3, 488-505	7
51	Genomic Screening for Pathogenic Transthyretin Variants Finds Evidence of Underdiagnosed Amyloid Cardiomyopathy From Health Records. 2021 , 3, 550-561	1
50	Incidence and Characterization of Concealed Cardiac Amyloidosis Among Unselected Elderly Patients Undergoing Post-mortem Examination. 2021 , 8, 749523	3
49	Targeted treatments of AL and ATTR amyloidosis. 2021 , 1	3
48	Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.. 2022 , 1-8	2
47	Is surgical myectomy challenged by emergence of novel drug therapy with mavacamten?. 2022 , 2184923221074414	
46	Trends in the amyloidosis mortality rate in Japan: A nationwide observational study from 1998 to 2019.. 2022 ,	0
45	Economic Issues in Heart Failure in the United States.. 2022 ,	2
44	Cost-Effectiveness of Antibiotic-Eluting Envelope for Prevention of Cardiac Implantable Electronic Device Infections in Heart Failure.. 2022 , CIRCOUTCOMES121008443	
43	Cardiac Amyloidosis Treatment.. 2022 , 18, 59-72	2
42	Estimated Cost-effectiveness of Medical Therapy, Sleeve Gastrectomy, and Gastric Bypass in Patients With Severe Obesity and Type 2 Diabetes.. 2022 , 5, e2148317	0
41	Therapeutic Strategy for Heart Failure with Reduced Ejection Fraction and Cardiac Amyloidosis.. 2022 , 63, 408-410	
40	Transthyretin deposition alters cardiomyocyte sarcomeric architecture, calcium transients, and contractile force.. 2022 , 10, e15207	1
39	RNA-targeting and gene editing therapies for transthyretin amyloidosis.. 2022 ,	6

38	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,		1
37	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,		15
36	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Circulation</i> , 2022 , 101161CIR0000000000001063	16.7	35
35	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. <i>Circulation</i> , 2022 , 101161CIR0000000000001062	16.7	6
34	Advances in Machine Learning Approaches to Heart Failure with Preserved Ejection Fraction.. 2022 , 18, 287-300		0
33	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.. 2022,		49
32	Quantifying is believing: Techniques for evaluating transthyretin cardiac amyloidosis burden for expanded clinical applications.. 2021 , 1		0
31	A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan.. 2022,		0
30	Treatment of Transthyretin Amyloid Cardiomyopathy: The Current Options, the Future, and the Challenges.. 2022 , 11,		4
29	The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives.. 2022 , 70, 248-257		0
28	OUP accepted manuscript.		0
27	Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.. 2022 , 11, e024566		0
26	Assessment and Management of Older Patients With Transthyretin Amyloidosis Cardiomyopathy: Geriatric Cardiology, Frailty Assessment and Beyond. 2022 , 9,		
25	Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis). 2022 , 94, 584-595		0
24	Early Experience of Tafamidis Treatment in Japanese Patients With Wild-Type Transthyretin Cardiac Amyloidosis From the Kochi Amyloidosis Cohort. 2022 ,		1
23	Lumbar stenosis due to wild-type transthyretin amyloid-induced thickening of the ligamentum flavum: a separate etiology from degeneration of intervertebral discs?. 2022 , 1-7		
22	Therapeutic value of tafamidis in patients with wild-type transthyretin amyloidosis (ATTRwt) with cardiomyopathy based on cardiovascular magnetic resonance (CMR) imaging.		0
21	The future of heart failure with preserved ejection fraction.		0

20	The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era. 2022,	0
19	Impact of Tafamidis on Survival in a Real World Community-Based Cohort. 2022, 101358	0
18	Modeling the Cost and Health Impacts of Diagnostic Strategies in Patients with Suspected Transthyretin Cardiac Amyloidosis. 2022, 11,	0
17	Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. 2022, 15,	1
16	99mTc-PYP SPECT and SPECT/CT quantitation for diagnosing cardiac transthyretin amyloidosis.	0
15	Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms. 2022, 4, 442-454	0
14	Overview of Current and Emerging Therapies for Amyloid Transthyretin Cardiomyopathy. 2022,	0
13	The Future for Patients With Transthyretin Cardiac Amyloidosis Is Looking Brighter. 2022, 146, 1671-1673	0
12	Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy. 2022, 23, 16145	0
11	2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. 2023,	1
10	Real-World Efficacy of Tafamidis in Patients With Transthyretin Amyloidosis and Heart Failure. 2023 , 48, 101667	0
9	Treatment of Transthyretin Amyloidosis. 2023, 235-276	0
8	Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020. 2023, 183, 290	0
7	Real-World Characteristics of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: An Analysis of Electronic Healthcare Records in the United States. 2023, 23, 197-206	0
6	Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction. 2023,	0
5	Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.	0
4	Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: a multicentre network study.	0
3	TTR Amyloidosis. 2023, 10, 101759	0

2 Kardiale Amyloidose. **2023**, 23, 39-43

o

1 Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin
Cardiomyopathy. **2023**, 15, 1129

o